Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
3.900
-0.100 (-2.50%)
Jun 5, 2025, 4:00 PM - Market closed
Jaguar Health Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 11.55 | 11.69 | 9.76 | 11.96 | 4.34 | 9.39 | Upgrade
|
| Revenue Growth (YoY) | 13.93% | 19.75% | -18.36% | 175.80% | -53.81% | 62.51% | Upgrade
|
| Cost of Revenue | 2.04 | 1.96 | 2.04 | 2.02 | 2.33 | 3.16 | Upgrade
|
| Gross Profit | 9.51 | 9.73 | 7.72 | 9.94 | 2 | 6.22 | Upgrade
|
| Selling, General & Admin | 25.59 | 24.02 | 23.05 | 26.71 | 26 | 20 | Upgrade
|
| Research & Development | 15.96 | 16.54 | 18.6 | 17.65 | 15.08 | 6.41 | Upgrade
|
| Operating Expenses | 41.55 | 40.57 | 41.64 | 44.35 | 41.08 | 26.41 | Upgrade
|
| Operating Income | -32.04 | -30.83 | -33.92 | -34.42 | -39.07 | -20.19 | Upgrade
|
| Interest Expense | - | -0.23 | -6.38 | -12.72 | -8.42 | -2.79 | Upgrade
|
| Interest & Investment Income | 0.44 | - | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -8.88 | -9.43 | -4.93 | 0.93 | -2.72 | -2.51 | Upgrade
|
| EBT Excluding Unusual Items | -40.48 | -40.5 | -45.23 | -46.21 | -50.21 | -25.48 | Upgrade
|
| Asset Writedown | - | - | -0.37 | - | - | -0.12 | Upgrade
|
| Other Unusual Items | - | 1.25 | 3.7 | -2.19 | -2.39 | -8.21 | Upgrade
|
| Pretax Income | -40.48 | -39.25 | -41.9 | -48.4 | -52.6 | -33.81 | Upgrade
|
| Earnings From Continuing Operations | -40.48 | -39.25 | -41.9 | -48.4 | -52.6 | -33.81 | Upgrade
|
| Minority Interest in Earnings | 0.75 | 0.76 | 0.6 | 0.94 | 0.01 | - | Upgrade
|
| Net Income | -39.73 | -38.49 | -41.3 | -47.45 | -52.6 | -33.81 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 4.84 | Upgrade
|
| Net Income to Common | -39.73 | -38.49 | -41.3 | -47.45 | -52.6 | -38.65 | Upgrade
|
| Shares Outstanding (Basic) | 0 | 0 | 0 | - | - | - | Upgrade
|
| Shares Outstanding (Diluted) | 0 | 0 | 0 | - | - | - | Upgrade
|
| Shares Change (YoY) | 934.82% | 1809.95% | - | - | - | - | Upgrade
|
| EPS (Basic) | -93.54 | -130.69 | -2678.17 | - | - | - | Upgrade
|
| EPS (Diluted) | -93.55 | -130.69 | -2678.17 | - | - | - | Upgrade
|
| Free Cash Flow | -29.67 | -29.4 | -33.24 | -33.18 | -34.98 | -15.29 | Upgrade
|
| Free Cash Flow Per Share | -69.86 | -99.82 | -2155.63 | - | - | - | Upgrade
|
| Gross Margin | 82.34% | 83.28% | 79.13% | 83.11% | 46.18% | 66.31% | Upgrade
|
| Operating Margin | -277.33% | -263.76% | -347.50% | -287.85% | -901.36% | -215.09% | Upgrade
|
| Profit Margin | -343.92% | -329.30% | -423.11% | -396.91% | -1213.26% | -411.81% | Upgrade
|
| Free Cash Flow Margin | -256.83% | -251.52% | -340.56% | -277.53% | -806.83% | -162.87% | Upgrade
|
| EBITDA | -30.16 | -28.93 | -31.91 | -32.43 | -37.36 | -18.46 | Upgrade
|
| EBITDA Margin | -261.07% | -247.51% | - | -271.28% | - | -196.69% | Upgrade
|
| D&A For EBITDA | 1.88 | 1.9 | 2.01 | 1.98 | 1.72 | 1.73 | Upgrade
|
| EBIT | -32.04 | -30.83 | -33.92 | -34.42 | -39.07 | -20.19 | Upgrade
|
| EBIT Margin | -277.33% | -263.76% | - | -287.85% | - | -215.09% | Upgrade
|
| Revenue as Reported | 11.55 | 11.69 | 9.76 | - | 4.34 | - | Upgrade
|
Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.